Immune Function in Young Children With Previous Pulmonary or Miliary/Meningeal Tuberculosis and Impact of BCG Vaccination
Authors: Sterling Timothy R. , Martire Terezinha , de Almeida Alexandre Silva , Ding Li , Greenberg David E. , Moreira Lorena Alves , Elloumi Houda , Torres Angelica P.V. , Sant'Anna Clemax Couto , Calazans Eliane , Paraguassu Geraldo , Gebretsadik Tebeb , Shintani Ayumi , Miller Kathleen , Kritski Afranio , e Silva Jose Roberto Lapa , Holland Steven M. 
Published: October 2007

OBJECTIVE. Children &lt;5 years old are at increased risk of miliary/meningeal tuberculosis, but the immunologic factors that place them at risk are unknown. BCG vaccine protects against miliary/meningeal tuberculosis, but the mechanism of protection is unknown. We assessed for abnormalities in immune response associated with miliary/meningeal or pulmonary tuberculosis in young children.

PATIENTS AND METHODS. We conducted a case-control study among HIV-seronegative Brazilian children who were &lt;5 years old. Case subjects had previous culture-confirmed or clinical miliary/meningeal tuberculosis. There were 2 sets of control subjects: those with culture-confirmed pulmonary tuberculosis and purified protein derivative–positive household contacts. All of the children had completed treatment. Peripheral blood mononuclear cells were stimulated (phytohemagglutinin, phytohemagglutinin + interleukin 12, lipopolysaccharide, lipopolysaccharide + interferon-γ, and purified protein derivative), and cytokine responses (interleukin 1β, interleukin-4, interleukin-6, interleukin-8, interleukin 10, interleukin 12, interferon-γ, tumor necrosis factor-α, and monocyte chemoattractant protein 1) were quantified by bead-based assay. Median cytokine responses were compared by the Kruskal-Wallis test. Multivariate analysis of variance accounted for multiple comparisons.

RESULTS. There were 18 case subjects with miliary/meningeal tuberculosis, 28 pulmonary control subjects, and 29 purified protein derivative–positive control subjects. The median age was 4.2 years. There was no difference in case and control subjects by age, gender, race, BMI, or median CD4 count. Twelve (67%) of 18 case subjects, 26 (93%) of 28 pulmonary control subjects, and 28 (97%) of 29 purified protein derivative–positive subjects had received BCG vaccine. No cytokine defects were identified in case subjects with miliary/meningeal tuberculosis compared with either set of control subjects. Pulmonary control subjects had uniformly higher monocyte chemoattractant protein 1 levels than case subjects with miliary/meningeal tuberculosis and purified protein derivative–positive control subjects, both at rest and with lipopolysaccharide, lipopolysaccharide + interferon-γ, and purified protein derivative stimulation. Pulmonary control subjects did not have a higher frequency of allele G in the −2518 monocyte chemoattractant protein 1 promoter polymorphism. Case subjects with miliary/meningeal tuberculosis who had received BCG vaccine (n = 12) had lower stimulated interleukin 8 production than children who did not receive BCG vaccine (n = 6).

CONCLUSIONS. Children with previous miliary/meningeal tuberculosis did not have a major defect in the cytokine pathways studied. Increased monocyte chemoattractant protein 1 levels were associated with pulmonary disease, occurred despite BCG vaccination, and were not associated with a polymorphism in the monocyte chemoattractant protein 1 promoter.